HUP0302675A2 - New crystalline modifications of lopinavir - Google Patents
New crystalline modifications of lopinavirInfo
- Publication number
- HUP0302675A2 HUP0302675A2 HU0302675A HUP0302675A HUP0302675A2 HU P0302675 A2 HUP0302675 A2 HU P0302675A2 HU 0302675 A HU0302675 A HU 0302675A HU P0302675 A HUP0302675 A HU P0302675A HU P0302675 A2 HUP0302675 A2 HU P0302675A2
- Authority
- HU
- Hungary
- Prior art keywords
- lopinavir
- modification
- range
- new crystalline
- crystal
- Prior art date
Links
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 title abstract 7
- 229960004525 lopinavir Drugs 0.000 title abstract 7
- 230000004048 modification Effects 0.000 title abstract 7
- 238000012986 modification Methods 0.000 title abstract 7
- 239000013078 crystal Substances 0.000 abstract 5
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya az (A) képletű lopinavir hidratált kristálymódosulata, a lopinavir szolvatált kristály módosulata, valamint alopinavir nem szolvatált kristály módosulata. A találmány tárgyatovábbá a lopinavir szolvatált kristály módosulata, amelynek a szilárdfázisú infravörös spektrumán van egy csúcs a 1661-1673 cm-1tartományban és van egy csúcs a 1645-1653 cm-1 tartományban és van egycsúcs a 1619-1629 cm-1 tartományban. A találmány a lopinavir nemszolvatált kristály módosulatára is vonatkozik. A lopinavir újkristály módosulatai a lopinavir tisztítására és elkülönítésérealkalmazhatók. ÓThe subject of the invention is the hydrated crystal modification of lopinavir of the formula (A), the solvated crystal modification of lopinavir, and the non-solvated crystal modification of alopinavir. The invention further relates to a modification of the solvated crystal of lopinavir, which has a peak in the range of 1661-1673 cm-1 and a peak in the range of 1645-1653 cm-1 and a single peak in the range of 1619-1629 cm-1 in its solid-phase infrared spectrum. The invention also relates to the modification of the unsolvated crystal of lopinavir. Lopinavir neocrystal modifications can be used to purify and isolate lopinavir. HE
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53825700A | 2000-03-30 | 2000-03-30 | |
| US09/793,536 US6608198B2 (en) | 2000-03-30 | 2001-02-27 | Crystalline pharmaceutical |
| PCT/US2001/009112 WO2001074787A2 (en) | 2000-03-30 | 2001-03-21 | Crystalline pharmaceutical |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302675A2 true HUP0302675A2 (en) | 2003-12-29 |
| HUP0302675A3 HUP0302675A3 (en) | 2004-03-29 |
Family
ID=27065762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302675A HUP0302675A3 (en) | 2000-03-30 | 2001-03-21 | New crystalline modifications of lopinavir |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1268442A2 (en) |
| JP (1) | JP2003529592A (en) |
| KR (1) | KR100773258B1 (en) |
| CN (2) | CN101066952A (en) |
| AR (2) | AR033360A1 (en) |
| AU (3) | AU5092001A (en) |
| BG (1) | BG107165A (en) |
| BR (1) | BR0109433A (en) |
| CA (1) | CA2403635A1 (en) |
| CZ (1) | CZ20023529A3 (en) |
| HU (1) | HUP0302675A3 (en) |
| IL (1) | IL151551A0 (en) |
| MX (1) | MXPA02009559A (en) |
| MY (1) | MY128296A (en) |
| NO (1) | NO325005B1 (en) |
| NZ (1) | NZ521183A (en) |
| PE (1) | PE20011232A1 (en) |
| PL (1) | PL359727A1 (en) |
| SA (2) | SA06270303B1 (en) |
| SK (1) | SK14832002A3 (en) |
| TW (1) | TWI284640B (en) |
| WO (1) | WO2001074787A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8445506B2 (en) | 2009-02-06 | 2013-05-21 | Hetero Research Foundation | Polymorphs of lopinavir |
| JP5789260B2 (en) * | 2009-08-27 | 2015-10-07 | メルク・シャープ・エンド・ドーム・コーポレイション | Method for preparing protease inhibitor of hepatitis C virus |
| CN112830899A (en) * | 2021-01-18 | 2021-05-25 | 合肥华方医药科技有限公司 | Novel lopinavir crystal form and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| AU8145198A (en) * | 1997-06-16 | 1999-01-04 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
-
2001
- 2001-03-07 MY MYPI20011034A patent/MY128296A/en unknown
- 2001-03-21 AU AU5092001A patent/AU5092001A/en active Pending
- 2001-03-21 SK SK1483-2002A patent/SK14832002A3/en not_active Application Discontinuation
- 2001-03-21 CA CA002403635A patent/CA2403635A1/en not_active Abandoned
- 2001-03-21 IL IL15155101A patent/IL151551A0/en unknown
- 2001-03-21 BR BR0109433-5A patent/BR0109433A/en not_active Application Discontinuation
- 2001-03-21 CN CNA2007101123988A patent/CN101066952A/en active Pending
- 2001-03-21 EP EP01924250A patent/EP1268442A2/en not_active Withdrawn
- 2001-03-21 NZ NZ521183A patent/NZ521183A/en not_active IP Right Cessation
- 2001-03-21 CN CNB018076882A patent/CN1330639C/en not_active Expired - Lifetime
- 2001-03-21 PL PL35972701A patent/PL359727A1/en not_active Application Discontinuation
- 2001-03-21 AU AU2001250920A patent/AU2001250920B2/en not_active Revoked
- 2001-03-21 JP JP2001572482A patent/JP2003529592A/en active Pending
- 2001-03-21 HU HU0302675A patent/HUP0302675A3/en unknown
- 2001-03-21 WO PCT/US2001/009112 patent/WO2001074787A2/en active IP Right Grant
- 2001-03-21 MX MXPA02009559A patent/MXPA02009559A/en active IP Right Grant
- 2001-03-21 KR KR1020027012849A patent/KR100773258B1/en active IP Right Grant
- 2001-03-21 CZ CZ20023529A patent/CZ20023529A3/en unknown
- 2001-03-29 AR ARP010101522A patent/AR033360A1/en not_active Application Discontinuation
- 2001-03-30 PE PE2001000299A patent/PE20011232A1/en not_active Application Discontinuation
- 2001-05-02 TW TW090107717A patent/TWI284640B/en active
- 2001-08-07 SA SA06270303A patent/SA06270303B1/en unknown
- 2001-08-07 SA SA01220270A patent/SA01220270B1/en unknown
-
2002
- 2002-09-30 NO NO20024679A patent/NO325005B1/en not_active Application Discontinuation
- 2002-10-03 BG BG107165A patent/BG107165A/en unknown
-
2005
- 2005-06-29 AR ARP050102702A patent/AR049560A2/en unknown
-
2006
- 2006-09-27 AU AU2006222711A patent/AU2006222711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02009559A (en) | 2003-05-21 |
| EP1268442A2 (en) | 2003-01-02 |
| IL151551A0 (en) | 2003-04-10 |
| AR049560A2 (en) | 2006-08-16 |
| BR0109433A (en) | 2004-08-10 |
| MY128296A (en) | 2007-01-31 |
| CZ20023529A3 (en) | 2003-02-12 |
| PE20011232A1 (en) | 2001-12-08 |
| SK14832002A3 (en) | 2003-02-04 |
| SA06270303B1 (en) | 2009-08-02 |
| NZ521183A (en) | 2004-03-26 |
| CN1422259A (en) | 2003-06-04 |
| AU2006222711A1 (en) | 2006-10-19 |
| AU5092001A (en) | 2001-10-15 |
| BG107165A (en) | 2003-07-31 |
| WO2001074787A3 (en) | 2002-02-07 |
| NO325005B1 (en) | 2008-01-14 |
| KR20030011807A (en) | 2003-02-11 |
| SA01220270B1 (en) | 2006-11-14 |
| PL359727A1 (en) | 2004-09-06 |
| AR033360A1 (en) | 2003-12-17 |
| CA2403635A1 (en) | 2001-10-11 |
| KR100773258B1 (en) | 2007-11-05 |
| HUP0302675A3 (en) | 2004-03-29 |
| AU2001250920B2 (en) | 2006-06-29 |
| CN1330639C (en) | 2007-08-08 |
| JP2003529592A (en) | 2003-10-07 |
| CN101066952A (en) | 2007-11-07 |
| TWI284640B (en) | 2007-08-01 |
| NO20024679D0 (en) | 2002-09-30 |
| NO20024679L (en) | 2002-09-30 |
| WO2001074787A2 (en) | 2001-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400336A2 (en) | Toothbrush cover | |
| HUP0300676A2 (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | |
| YU83602A (en) | Phenylglycine derivatives | |
| DE69927805D1 (en) | NEW FAT ANALOGUE FOR THE TREATMENT OF SECONDARY RESTENOSIS | |
| ATE302773T1 (en) | PIPERAZINE AND PIPERIDINE DERIVATIVES AS AGONISTS OF THE MELANOCORTIN RECEPTOR | |
| HUP0401716A2 (en) | A package for an ostomy appliance | |
| UA81603C2 (en) | Urea derivatives as integrin alpha 4 antagonists | |
| GB2422956B (en) | Use of silicon block process step to camouflage a false transistor | |
| EP1569684A4 (en) | Use of hmgb fragments as anti-inflammatory agents | |
| HUP0203521A2 (en) | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cept inhibitor, process for its preparation, pharmaceutical composition containing the same and its use | |
| ATE334645T1 (en) | RING FOR DEFORMING THE STOMACH | |
| HUP0301870A2 (en) | Imidazole and benzimidazole caspase inhibitors and uses thereof | |
| HUP0302675A2 (en) | New crystalline modifications of lopinavir | |
| MY133969A (en) | Indoloquinazolinones | |
| MY145650A (en) | Azeotrope compositions comprising nonafluoropentene and hydrogen fluoride and uses thereof | |
| HUP0103072A2 (en) | Use of growth hormone secretagogues | |
| MXPA04001035A (en) | Purification and crystalline forms of zaleplon. | |
| DE50308707D1 (en) | REMOVAL AND MODIFICATION OF SILICATES AND SILICONES BY SILICASE AND USE OF THE REVERSIBLE ENZYME | |
| EA200700198A1 (en) | PREPARATION OF HYDROCHLORIDES OF DERIVATIVE TETRAZOL | |
| DK1326838T3 (en) | Novel crystal forms of an inhibitor of factor xa | |
| DE60211495D1 (en) | XANTHINE-GLYCOL DERIVATIVES FOR THE TREATMENT OF REIZDARY SYNDROME | |
| HK1070686A1 (en) | Gas plug connector. | |
| AU2001287820A1 (en) | Use of lipopeptides for immunotherapy of hiv-positive subjects | |
| DK1274426T3 (en) | Use of thioamide oxazolidinones in the treatment of bone resorption and osteoporosis | |
| EP1945648A4 (en) | Derivatives of 4,6-disubstituted 1,2,4-triazolo-1,3,4-thiadiazole, a process and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |